Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19080623 | 0.85 | GAA (0.48) | GAACETPL3MBTL1MAPT | |
| SCHEMBL27416375 | 0.85 | GAA (0.48) | GAACETPL3MBTL1MAPT | |
| SCHEMBL19090958 | 0.83 | GAA (0.46) | GAACETPL3MBTL1TYRMAPT | |
| SCHEMBL21211618 | 0.82 | GAA (0.54) | GAACETPL3MBTL1TYRMAPT | |
| SCHEMBL3791015 | 0.82 | GAA (0.54) | GAACETPL3MBTL1TYRMAPT | |
| SCHEMBL8508353 | 0.82 | GAA (0.54) | GAACETPL3MBTL1TYRMAPT | |
| SCHEMBL8812577 | 0.82 | GAA (0.54) | GAACETPL3MBTL1TYRMAPT | |
| SCHEMBL25416868 | 0.81 | SELL (0.44) | GAACETP | |
| SCHEMBL14477411 | 0.80 | ALDH1A1 (0.46) | GAALGALS8LGALS3LGALS4 | |
| SCHEMBL12338088 | 0.80 | ALDH1A1 (0.46) | GAALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | GAA 448/4885CETP 124/4885L3MBTL1 2440/4885 |
| US-10246478-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | GAA 448/4885CETP 124/4885L3MBTL1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.